Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06546527 | Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | not yet recruiting | Early Phase 1 | 12 | Peking University First HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06525714 | Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer | not yet recruiting | Early Phase 1 | 302 | The First Hospital of Jilin UniversityOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06432075 | Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer | not yet recruiting | Early Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | May 29, 2024 | clinicaltrials |
| NCT06370026 | KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 12 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06396481 | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma(CSAγδTBMG) | not yet recruiting | Early Phase 1 | 25 | Beijing Tiantan HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT03763396 | Azoles Targeting Recurrent High Grade Gliomas | not yet recruiting | Early Phase 1 | 30 | University Health Network, TorontoOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06212388 | Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma | not yet recruiting | Early Phase 1 | 10 | Xijing HospitalOTHER | 0 | Jan 25, 2024 | clinicaltrials |
| NCT06196658 | Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | not yet recruiting | Early Phase 1 | 6 | Zhang Xiaofeng,MDOTHER | 0 | Jan 9, 2024 | clinicaltrials |
| NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | not yet recruiting | Early Phase 1 | 30 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05979857 | Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma | not yet recruiting | Early Phase 1 | 72 | Salarius Pharmaceuticals, LLCINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06097455 | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma(CARTD-BG-1) | not yet recruiting | Early Phase 1 | 40 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05447234 | TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy | not yet recruiting | Early Phase 1 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 16, 2023 | clinicaltrials |
| NCT05505812 | Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer | not yet recruiting | Early Phase 1 | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04658004 | NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04599543 | IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 9, 2024source: clinicaltrials